Sustained antihypertensive activity of telmisartan compared with valsartan

[en] Early morning bood pressure (BP) surge and 24h mean BP are linked to target-organ damage and cardiovascular events. Antihypertensive agents should sustain BP control, particularly in the last 6h of the dosing interval or if dosing is missed. The efficacies of the long half-life telmisartan compared with shorter half-life valsartan in the last 6h of the dosing interval following active treatment and during 24h after a missed dose were compared.

Disciplines :

Urology & nephrology

Author, co-author :

Lacourcière, Yves; CHU de Quebec Sainte-Foy - Canada > Hypetension Research Unit

Krzesinski, Jean-Marie ; Université de Liège - ULiège > Néphrologie

White, William B.; University of Connecticut School of Medicine - USA

Davidai, Giora; Boehringer IngelheimPharmaceuticals Inc. Connecticut - USA > Research and Development

Schumacher, Helmut; Boehringer Ingelheim GmbH and Pharma KG - Germany > Medical Data Services Department

Language :

English

Title :

Sustained antihypertensive activity of telmisartan compared with valsartan

Publication date :

2004

Journal title :

Blood Pressure Monitoring

ISSN :

1359-5237

Publisher :

Lippincott Williams & Wilkins, Hagerstown, United States - Maryland

Volume :

Pages :

203-210

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 13 September 2010

Statistics

Number of views

148 (2 by ULiège)

Number of downloads

2 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Neutel JM, Smith DH. The circadian pattern of blood pressure: cardiovascular risk and therapeutic opportunities. Curr Opin Nephrol Hypertens 1997; 6:250-256.
Marler JR, Price TR, Clark GL, Muller JE, Robertson T, Mohr JP, et al. Morning increase in onset of ischemic stroke. Stroke 1989; 20:473-476.
Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989; 79:733-743.
White WB. Circadian variation of blood pressure: clinical relevance and implications for cardiovascular chronotherapeutics. Blood Press Monit 1997; 2:47-51.
Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107:1401-1406.
Millar-Craig M, Bishop C, Raftery E. Circadian variation of blood pressure. Lancet 1978; 1:795-797.
White WB. Ambulatory blood-pressure monitoring in clinical practice. N Engl J Med 2003; 348:2377-2378.
Chung O, Unger T. Pharmacology of angiotensin receptors and AT 1 receptor blockers. Basic Res Cardiol 1998; 93(suppl 2):15-23.
Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs 2001; 61:1501-1529.
Gardner SF, Franks AM. Olmesartan medoxomil: the seventh angiotensin receptor antagonist. Ann Pharmacother 2003; 37:99-105.
Littlejohn T, Mroczek W, Marbury T, VanderMaelen CP, Dubiel RF. A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Can J Cardiol 2000; 16:1123-1132.
Smith DH, Cramer MJ, Neutel JM, Hettiarachchi R, Koval S. Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies. Blood Press Monit 2003; 8:111-117.
Neutel JM. Use of ambulatory blood pressure monitoring to evaluate the selective angiotensin II receptor antagonist, telmisartan, and other antihypertensive drugs. Blood Press Monit 2000; 5(suppl 1):S35-S40.
Lacourcière Y, Lenis J, Orchard R, Lewanczuk R, Houde M, Pesant Y, et al. A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. Blood Press Monit 1998; 3:295-302.
White WB, Lacourcière Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens 2004; 17:347-353.
Krzesinski J-M, White WB, Davidai G, Schumacher H, Lacourcière Y. Sustained antihypertensive activity of telmisartan versus valsartan [abstract]. Hypertension 2003; 42(suppl 4):640.
Markham A, Goa KL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997; 54:299-311.
Flesch G, Muller P, Lloyd P. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol 1997; 52:115-120.
Medical dictionary for regulatory activities terminology (MedDRA). Version 3.3. Washington DC: Food and Drug Adminstration; 2000.
SAS [computer program]. Version 8. Cary, North Carolina: SAS Institute Inc., 1999-2001.
Anwar YA, White WB. Chronotherapeutics for cardiovascular disease. Drugs 1998; 55:631-643.
Tofler GH, Brezinski D, Schafer AI, Czeisler CA, Rutherford JD, Willich SN, et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med 1987; 316:1514-1518.
Dodt C, Breckling U, Derad I, Fehm HL, Born J. Plasma epinephrine and norepinephrine concentrations of healthy humans associated with nighttime sleep and morning arousal. Hypertension 1997; 30:71-76.
Rudd P. Clinicians and patients with hypertension: unsettled issues about compliance. Am Heart J 1995; 130:572-579.
Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157:2413-2446.
Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:1755-1762.
Flack JM, Novikov SV, Ferrario CM. Benefits of adherence to antihypertensive drug therapy. Eur Heart J 1996; 17(suppl A):16-20.